BCL11A和MDR1表达对接受化疗的急性髓性白血病患者具有预后影响。
BCL11A and MDR1 expressions have prognostic impact in patients with acute myeloid leukemia treated with chemotherapy.
作者信息
Xutao Guo, PengCheng Shi, Yin Li, Huijuan Dong, Yan Wang, Haiqing Zheng, Bing Xu
机构信息
Department of Hematology, Nanfang Hospital, Southern Medical University, 510515, Guan Zhou City, PR China.
Department of hematology The First Affiliated Hospital of Xiamen University, 361001, XiaMen City, PR China.
出版信息
Pharmacogenomics. 2018 Mar;19(4):343-348. doi: 10.2217/pgs-2017-0157. Epub 2018 Feb 22.
UNLABELLED
Acute myeloid leukemia (AML) is a heterogeneous malignant disease. Many different genetic factors can affect a patient's clinical outcome.
AIM
The aim of this study was to assess the expression of BCL11A and MDR1 in AML patients, and its relation to clinical outcome.
MATERIALS & METHODS: We grouped the 142 patients by the levels of BCL11A and MDR1 and identified three different subgroups: high BCL11A and high MDR1 (n = 47), low BCL11A and low MDR1 (n = 47) and high BCL11A alone or high MDR1 alone (n = 48).
RESULTS
The results showed that AML patients with high BCL11A and MDR1 expression had the lowest complete remission and highest relapse rate. The median overall survival of the high BCL11A and high MDR1 group was the shortest among the three groups. With regards to overall survival, there were also significant differences among the groups (p < 0.001).
CONCLUSION
High BCL11A and MDR1 expression was associated with a poor response to chemotherapy, and identified a subset of AML patients with a very poor prognosis.
未标记
急性髓系白血病（AML）是一种异质性恶性疾病。许多不同的遗传因素会影响患者的临床结局。
目的
本研究旨在评估AML患者中BCL11A和MDR1的表达及其与临床结局的关系。
材料与方法
我们根据BCL11A和MDR1水平将142例患者分组，确定了三个不同亚组：高BCL11A和高MDR1（n = 47）、低BCL11A和低MDR1（n = 47）以及单独高BCL11A或单独高MDR1（n = 48）。
结果
结果显示，BCL11A和MDR1表达高的AML患者完全缓解率最低，复发率最高。高BCL11A和高MDR1组的中位总生存期在三组中最短。在总生存期方面，各组之间也存在显著差异（p < 0.001）。
结论
高BCL11A和MDR1表达与化疗反应不佳相关，并确定了一组预后非常差的AML患者。
Zotero 插件